Continuing challenges for the clinical laboratory for detection of carbapenem-resistant enterobacteriaceae

Abstract

Detecting carbapenem-resistant Enterobacteriaceae (CRE) can be difficult. In particular, the absence of FDA-cleared automated antimicrobial susceptibility test (AST) devices that use revised Clinical and Laboratory Standards Institute (CLSI) carbapenem breakpoints for Enterobacteriaceae and the lack of active surveillance tests hamper the clinical laboratory.